BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19401874)

  • 21. PAX3 expression in primary melanomas and nevi.
    Plummer RS; Shea CR; Nelson M; Powell SK; Freeman DM; Dan CP; Lang D
    Mod Pathol; 2008 May; 21(5):525-30. PubMed ID: 18327212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
    Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
    Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter.
    Galibert MD; Yavuzer U; Dexter TJ; Goding CR
    J Biol Chem; 1999 Sep; 274(38):26894-900. PubMed ID: 10480898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.
    He SJ; Stevens G; Braithwaite AW; Eccles MR
    Mol Cancer Ther; 2005 Jun; 4(6):996-1003. PubMed ID: 15956257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pax3 functions at a nodal point in melanocyte stem cell differentiation.
    Lang D; Lu MM; Huang L; Engleka KA; Zhang M; Chu EY; Lipner S; Skoultchi A; Millar SE; Epstein JA
    Nature; 2005 Feb; 433(7028):884-7. PubMed ID: 15729346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro.
    Cook AL; Smith AG; Smit DJ; Leonard JH; Sturm RA
    Exp Cell Res; 2005 Aug; 308(1):222-35. PubMed ID: 15896776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoints of melanocyte stem cell development.
    Sommer L
    Sci STKE; 2005 Aug; 2005(298):pe42. PubMed ID: 16118396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
    Kubic JD; Lui JW; Little EC; Ludvik AE; Konda S; Salgia R; Aplin AE; Lang D
    J Biol Chem; 2015 Sep; 290(36):21901-14. PubMed ID: 26205821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAX3 and ETS1 synergistically activate MET expression in melanoma cells.
    Kubic JD; Little EC; Lui JW; Iizuka T; Lang D
    Oncogene; 2015 Sep; 34(38):4964-74. PubMed ID: 25531327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3.
    Watanabe A; Takeda K; Ploplis B; Tachibana M
    Nat Genet; 1998 Mar; 18(3):283-6. PubMed ID: 9500554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel expression patterns of Pax3/Pax7 in early trunk neural crest and its melanocyte and non-melanocyte lineages in amniote embryos.
    Lacosta AM; Muniesa P; Ruberte J; Sarasa M; Domínguez L
    Pigment Cell Res; 2005 Aug; 18(4):243-51. PubMed ID: 16029418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription.
    Dong L; Li Y; Cao J; Liu F; Pier E; Chen J; Xu Z; Chen C; Wang RA; Cui R
    Cell Death Differ; 2012 Apr; 19(4):616-22. PubMed ID: 21997191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haplosufficiency of PAX3 for melanoma development in Tyr: NRASQ61K; Cdkn2a-/- mice allows identification and sorting of melanoma cells using a Pax3GFP reporter allele.
    Campagne C; Reyes-Gomez E; Loiodice S; Gadin S; Ezagal J; Bernex F; Abitbol M; Louise A; Beermann F; Panthier JJ; Aubin-Houzelstein G; Egidy G
    Melanoma Res; 2016 Feb; 26(1):12-20. PubMed ID: 26587692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perplexing Pax: from puzzle to paradigm.
    Blake JA; Thomas M; Thompson JA; White R; Ziman M
    Dev Dyn; 2008 Oct; 237(10):2791-803. PubMed ID: 18816860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells.
    Kubic JD; Mascarenhas JB; Iizuka T; Wolfgeher D; Lang D
    Mol Cancer Res; 2012 Aug; 10(8):1065-76. PubMed ID: 22679108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of PAX3 by TGF-beta modulates melanocyte viability.
    Yang G; Li Y; Nishimura EK; Xin H; Zhou A; Guo Y; Dong L; Denning MF; Nickoloff BJ; Cui R
    Mol Cell; 2008 Nov; 32(4):554-63. PubMed ID: 19026785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest.
    Manderfield LJ; Engleka KA; Aghajanian H; Gupta M; Yang S; Li L; Baggs JE; Hogenesch JB; Olson EN; Epstein JA
    Cell Rep; 2014 Dec; 9(5):1885-1895. PubMed ID: 25466249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation by Pax3 and TGFbeta2 signaling: a potential gene regulatory network in neural crest development.
    Nakazaki H; Shen YW; Yun B; Reddy A; Khanna V; Mania-Farnell B; Ichi S; McLone DG; Tomita T; Mayanil CS
    Int J Dev Biol; 2009; 53(1):69-79. PubMed ID: 19123128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations.
    Corry GN; Underhill DA
    Pigment Cell Res; 2005 Dec; 18(6):427-38. PubMed ID: 16280008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAX transcription factors in neural crest development.
    Monsoro-Burq AH
    Semin Cell Dev Biol; 2015 Aug; 44():87-96. PubMed ID: 26410165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.